Search
Close this search box.

Petroutsas to lead U.S. commercial operations at Astellas

ARTICLE | Management Tracks

Plus: Evan Ballantyne named CFO at Hansa and updates from BostonGene and InflaRx

By Gunjan Ohri, Data Content Analyst

February 24, 2024 1:24 AM UTC

Astellas Pharma Inc. (Tokyo:4503) hired Michael Petroutsas as head of U.S. commercial at its Astellas Pharma US Inc. unit. Petroutsas was SVP, U.S. specialty and oncology business at GSK plc (LSE:GSK; NYSE:GSK). He succeeds Mark Reisenauer, who is leaving at the end of March.

Evan Ballantyne will become CFO of  Hansa Biopharma AB (SSE:HNSA) on March 1, succeeding Donato Spota.  Ballantyne was SVP, CFO at Gain Therapeutics Inc. (NASDAQ:GANX)…